AstraZeneca Submits NDA For Sustained Release Formulation Of SEROQUEL(R) For Schizophrenia Treatment

... AstraZeneca (NYSE:AZN) today announced that it has submitted a New Drug Application (NDA)with the U.S. Food and Drug Administration (FDA) for a sustained releaseformulation of SEROQUEL(R) (quetiapine fumarate) - SEROQUEL(R) SR in thetreatment of patients with schizophrenia. [click link for full article] ...